Profound Medical Corp. (NASDAQ:PROF) on Tuesday announced that Johns Hopkins Hospital has performed its first commercial prostate cancer treatment using the company's TULSA-PRO system, marking a key adoption milestone for the MRI-guided, incision-free ablation technology.
The procedure, conducted on Jan. 6, 2026, coincides with the opening of Johns Hopkins Medicine's new interventional MRI (iMRI) suite and represents the prestigious institution's first use of TULSA-PRO outside of clinical trials.
TULSA-PRO employs robotically controlled directional ultrasound combined with real-time MRI thermography to precisely target and ablate prostate tissue.
The outpatient procedure typically involves no blood loss, no overnight hospital stay and significantly reduced risk of side effects such as incontinence or erectile dysfunction compared with traditional surgery or radiation
Johns Hopkins previously participated in the pivotal TACT trial that supported the system's FDA de novo clearance in 2019.
The announcement highlights accelerating U.S. commercial traction for TULSA-PRO following recent reimbursement advancements, including new Category 1 CPT codes effective January 2024.